Showing results (331-340 of 398) with videos related to
Sort By:
Pageof 40
Cancer Chemotherapy and Pharmacology|December 25, 2009
Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapySeung Tae Kim, Jeeyun Lee, Se Hoon Park, et al.Cancer|October 28, 2024
Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: Post hoc analysis of KEYNOTE-052 and LEAP-011Peter H O'Donnell, Yohann Loriot, Tibor Csoszi, et al.Medical Oncology (Northwood, London, England)|December 2, 2009
The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancerSeung Tae Kim, Jeeyun Lee, Se Hoon Park, et al.European Urology Oncology|July 20, 2025
Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate CancerNiven Mehra, Emmanuel S Antonarakis, Se Hoon Park, et al.The Lancet. Oncology|December 24, 2011
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 studyJeeyun Lee, Se Hoon Park, Heung-Moon Chang, et al.Oncotarget|October 10, 2015
Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patientsSeung Tae Kim, Won-Suk Lee, Richard B Lanman, et al.The Lancet. Oncology|September 2, 2022
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialThomas Powles, Piotr Tomczak, Se Hoon Park, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2024
Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274Matthew D Galsky, Johannes Alfred Witjes, Jürgen E Gschwend, et al.Journal of Cancer|June 22, 2016
Prognostic Model to Predict Survival Outcome for Curatively Resected Liposarcoma: A Multi-Institutional ExperienceYoon Jung Oh, Seong Yoon Yi, Ki Hyang Kim, et al.JAMA|April 8, 2020
Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical TrialWilliam D Tap, Andrew J Wagner, Patrick Schöffski, et al.Pageof 40